Literature DB >> 9515787

Heparan/chondroitin/dermatan sulfate primer 2-(6-hydroxynaphthyl)-O-beta-D-xylopyranoside preferentially inhibits growth of transformed cells.

K Mani1, B Havsmark, S Persson, Y Kaneda, H Yamamoto, K Sakurai, S Ashikari, H Habuchi, S Suzuki, K Kimata, A Malmström, G Westergren-Thorsson, L A Fransson.   

Abstract

Xylose forms the direct carbohydrate-protein link in extra- or pericellular proteoglycans (PGs) that are substituted with either chondroitin sulfate (CS)/dermatan sulfate (DS) and/or heparan sulfate (HS). Cell surface PGs carrying HS are important regulators of cell growth. Xylose coupled to an aromatic compound can enter cells and initiate either CS/DS synthesis or both HS and CS/DS synthesis, depending on the nature of the aromatic adduct. Here, we show that 2-(6-hydroxynaphthyl)-O-beta-D-xylopyranoside, which can prime both types of glycan chains, inhibits growth of a set of normal and transformed cells. Transformed cells are preferentially inhibited, and at a concentration of 0.15-0.20 mM xyloside, transformed cells are totally growth arrested, whereas normal cells are only < or = 50% inhibited. No inhibition of growth is observed with the stereoisomeric 2-(6-hydroxynaphthyl)-O-beta-L-xylopyranoside, which does not prime glycosaminoglycan synthesis at all; with the nonhydroxylated 2-naphthyl-O-beta-D-xylopyranoside, which only primes CS/DS synthesis under these conditions; or with p-nitrophenyl-O-beta-D-xylopyranoside, which is known to prime only CS/DS synthesis. We conclude that growth inhibition is due to priming of HS and/or CS/DS synthesis, which may either lead to the formation of specific antiproliferative glycans or glycan fragments or to interference with endogenous PG synthesis and turnover.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9515787

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  LC-MS/MS characterization of xyloside-primed glycosaminoglycans with cytotoxic properties reveals structural diversity and novel glycan modifications.

Authors:  Andrea Persson; Alejandro Gomez Toledo; Egor Vorontsov; Waqas Nasir; Daniel Willén; Fredrik Noborn; Ulf Ellervik; Katrin Mani; Jonas Nilsson; Göran Larson
Journal:  J Biol Chem       Date:  2018-05-08       Impact factor: 5.157

2.  Identification of key functional residues in the active site of human {beta}1,4-galactosyltransferase 7: a major enzyme in the glycosaminoglycan synthesis pathway.

Authors:  Ibtissam Talhaoui; Catherine Bui; Rafael Oriol; Guillermo Mulliert; Sandrine Gulberti; Patrick Netter; Michael W H Coughtrie; Mohamed Ouzzine; Sylvie Fournel-Gigleux
Journal:  J Biol Chem       Date:  2010-09-14       Impact factor: 5.157

3.  Xyloside-primed Chondroitin Sulfate/Dermatan Sulfate from Breast Carcinoma Cells with a Defined Disaccharide Composition Has Cytotoxic Effects in Vitro.

Authors:  Andrea Persson; Emil Tykesson; Gunilla Westergren-Thorsson; Anders Malmström; Ulf Ellervik; Katrin Mani
Journal:  J Biol Chem       Date:  2016-05-12       Impact factor: 5.157

4.  Glycosaminoglycan secretion in xyloside treated polarized human colon carcinoma Caco-2 cells.

Authors:  Kristian Prydz; Tram T Vuong; Svein O Kolset
Journal:  Glycoconj J       Date:  2009-12       Impact factor: 2.916

5.  Probing the acceptor active site organization of the human recombinant β1,4-galactosyltransferase 7 and design of xyloside-based inhibitors.

Authors:  Mineem Saliba; Nick Ramalanjaona; Sandrine Gulberti; Isabelle Bertin-Jung; Aline Thomas; Samir Dahbi; Chrystel Lopin-Bon; Jean-Claude Jacquinet; Christelle Breton; Mohamed Ouzzine; Sylvie Fournel-Gigleux
Journal:  J Biol Chem       Date:  2015-01-07       Impact factor: 5.157

6.  Azide-Functionalized Naphthoxyloside as a Tool for Glycosaminoglycan Investigations.

Authors:  Daniel Willén; Roberto Mastio; Zackarias Söderlund; Sophie Manner; Gunilla Westergren-Thorsson; Emil Tykesson; Ulf Ellervik
Journal:  Bioconjug Chem       Date:  2021-11-16       Impact factor: 4.774

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.